文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

南非含利奈唑胺或乙硫异烟胺的全口服9个月方案治疗耐多药或利福平耐药结核:回顾性队列研究

Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该回顾性队列研究纳入南非2017年接受含乙硫异烟胺(4个月)全口服9个月方案和2019年接受含利奈唑胺(2个月)全口服9个月方案的耐多药/利福平耐药结核患者,采用倾向评分逆概率加权调整混杂。结果显示两组治疗成功、死亡和治疗失败无显著差异,利奈唑胺组失访更常见但估计不精确。结论认为利奈唑胺是该短程方案中乙硫异烟胺可接受的替代选择。

要点

  • 含利奈唑胺方案与含乙硫异烟胺方案相比,治疗成功无显著差异(aRR=0.96,95%CI 0.91-1.01)。
  • 两组死亡无显著差异(aRR=1.01,95%CI 0.87-1.17),治疗失败无显著差异(aRR=0.87,95%CI 0.44-1.75)。
  • 利奈唑胺组失访更常见但估计不精确(aRR=1.22,95%CI 0.99-1.50)。

核心结论

  • 以利奈唑胺替代乙硫异烟胺作为全口服9个月方案的一部分,治疗成功和生存无显著差异。
  • 利奈唑胺是该短程方案中治疗耐多药/利福平耐药结核可接受的乙硫异烟胺替代选择。

研究设计与样本

  • 回顾性队列研究,纳入2017年1月1日至12月31日和2019年1月1日至12月31日期间在南非接受耐多药/利福平耐药结核治疗的患者。
  • 乙硫异烟胺队列817例(9个月方案含乙硫异烟胺4个月),利奈唑胺队列4244例(9个月方案含利奈唑胺2个月),方案其余相同。
  • 采用倾向评分逆概率加权调整潜在混杂,使用对数二项回归模型估计24个月结局的校正相对风险(aRR)。
  • 不良事件数据仅利奈唑胺队列可得。

主要发现

  • 治疗成功:利奈唑胺组 vs 乙硫异烟胺组 aRR=0.96(95%CI 0.91-1.01),无显著差异证据。
  • 死亡:利奈唑胺组 vs 乙硫异烟胺组 aRR=1.01(95%CI 0.87-1.17),无显著差异证据。
  • 治疗失败:利奈唑胺组 vs 乙硫异烟胺组 aRR=0.87(95%CI 0.44-1.75),无显著差异证据。
  • 失访:利奈唑胺组较乙硫异烟胺组更常见,但估计不精确(aRR=1.22,95%CI 0.99-1.50)。

临床怎么用

  • 作者认为利奈唑胺是此短程方案中治疗耐多药/利福平耐药结核可接受的乙硫异烟胺替代选择。

局限性

  • 失访估计不精确(aRR=1.22,95%CI 0.99-1.50)。
  • 不良事件数据仅利奈唑胺队列可得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2019, the South African tuberculosis program replaced ethionamide with linezolid as part of an all-oral 9-month regimen. We evaluated treatment outcomes for patients assigned to regimens including linezolid in 2019 and ethionamide in 2017. METHODS: This retrospective cohort study included patients treated for multidrug-resistant/rifampicin-resistant tuberculosis throughout South Africa between 1 January and 31 December 2017 and 1 January to 31 December 2019. The cohort treated with a 9-month regimen containing ethionamide for four months, was compared with a cohort treated with a 9-month regimen containing linezolid for 2 months. The regimens were otherwise identical. Inverse probability weighting of propensity scores was used to adjust for potential confounding. A log-binomial regression model was used to estimate adjusted relative risk (aRR) comparing 24-month outcomes between cohorts including treatment success, death, loss to follow up, and treatment failure. Adverse event data were available for the linezolid cohort. FINDINGS: In total, 817 patients were included in the cohort receiving ethionamide and 4244 in the cohort receiving linezolid. No evidence for a difference was observed between linezolid and ethionamide regimens for treatment success (aRR = 0.96, 95% confidence interval [CI] .91-1.01), death (aRR = 1.01, 95% CI .87-1.17) or treatment failure (aRR = 0.87, 95% CI .44-1.75). Loss to follow-up was more common in the linezolid group, although estimates were imprecise (aRR = 1.22, 95% CI .99-1.50). CONCLUSIONS: No significant differences in treatment success and survival were observed with substitution of linezolid for ethionamide as a part of an all-oral 9-month regimen. Linezolid is an acceptable alternative to ethionamide in this shorter regimen for treatment of multidrug-resistant/rifampicin-resistant tuberculosis.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Morgan H, Ndjeka N, Hasan T, et al. Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study. Clin Infect Dis. 2024. PMID: 38525535. doi:10.1093/cid/ciae145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。